

Special Issue

Focus on Antibiotics – New Challenges and Steps Forward in Discovery and Development

Message from the Guest Editors

The design of new antibiotics is still considered the primary weapon in the fight against the growing phenomenon of bacterial resistance to known antibiotics. Pharmaceutical research is focused on new approaches that lead to novel successful compounds within a short time. A new trend is targeting old antibiotics and other compounds from various therapeutic classes for optimization and repositioning. Hybrid drugs that incorporate two active compounds into a single molecule could expand antibacterial activity and prevent bacterial resistance. Different metal complexes of antibiotics or other organic substances have already shown potential for antibacterial activity. Nanoparticles (e.g., silver nanoparticles) are very attractive in multiple medical applications. Thus, in the last decade, new classes of antibiotics have been sought. New types of compounds with antibacterial activity are in various research stages: proteic compounds, siderophores, quinoxolidinones, natural antibiotics, antibiotic resistance breakers, and others. This Special Issue aims to present the latest efforts towards the discovery of new antibiotics.

Guest Editors

Prof. Dr. Aura Rusu

Prof. Dr. Valentina Uivarosi

Dr. Corneliu Tanase

Deadline for manuscript submissions

closed (30 October 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/71798

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).